Maze Therapeutics (MAZE) Cash from Operations (2024 - 2026)

Maze Therapeutics has disclosed Cash from Operations across 3 years of filings, most recently posting 39113000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 39113000.0, down 32.51% year-over-year; the trailing twelve-month figure through Mar 2026 was 121537000.0 (down 273.93% YoY), and the FY2025 annual result was 111940000.0, down 247.38% from the prior year.
• Cash from Operations came in at 39113000.0 for Q1 2026 at Maze Therapeutics, down from 27730000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 145048000.0 in Q2 2024 to a low of 39113000.0 in Q1 2026.
• The 3-year median for Cash from Operations is 24642000.0 (2025), against an average of 8344333.33.
• Peak annual rise in Cash from Operations reached 6.19% in 2025, while the deepest fall reached 120.72% in 2025.
• Maze Therapeutics' Cash from Operations stood at 22452000.0 in 2024, then decreased by 23.51% to 27730000.0 in 2025, then tumbled by 41.05% to 39113000.0 in 2026.
• The last three Cash from Operations figures came in at 39113000.0 (Q1 2026), 27730000.0 (Q4 2025), and 24642000.0 (Q3 2025), per Business Quant data.